Chronic Renal Failure Clinical Trial
Chronic renal failure is a syndrome that renal function is decreased, and the patient number
is increasing. In addition, patients on dialysis have also increased. Depending on the
chronic renal failure aggravated, the deterioration of life caused by the conduct of
dialysis patients is caused. In addition, a problem in dialysis treatment is ongoing
economic burden surface to increase the life of the patient and family. A solution to this
problem is, or stops the progression of chronic renal failure prior to dialysis, it is
necessary to delay. As a treatment for inhibiting the progression of chronic renal failure
is present, along with diet and blood pressure-lowering drugs or a drug therapy used by
kremezin. However, the effect is not enough, new drug development is required.
HD-003 is a novel compound, and found to inhibit the renal failure progression. It was found
during the search active substance that appear when the inflammation in animals. The
investigators confirmed that the substance is present in the urine of a person during the
study, and later established a link between kidney disease hypotheses. When performing the
test in animal model renal failure, chronic renal Through the non-clinical testing of the
HD-003(general toxicity studies, reproductive, developmental toxicity test, mutagenicity
test and antigen tests) showed that a very low toxicity. When going through the review of
the safety and pharmacokinetic Phase 1 clinical study, it was confirmed a very satisfactory
safety and tolerability. And pharmacokinetic results from the body's absorption in healthy
subjects had been done well, a linear correlation was observed. Finally, it was confirmed
that the most rapidly excreted into the urine.
This study is a Phase 2a clinical trials performed in patients with chronic renal failure in
3, 4 steps. The evaluation of changes in serum creatinine(sCr) in vivo indicator of renal
failure according to the progress. Evaluating the inhibitory effect of HD-003 renal failure
progression and dose setting, and to determine the safety.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02565459 -
MSC and Kidney Transplant Tolerance (Phase A)
|
Phase 1 | |
| Recruiting |
NCT02356419 -
rESP Medication With a Single Intravenous Administration and Dose Escalation to Explore the Tolerability ,Safety and Pharmacokinetic Characteristics
|
Phase 1 | |
| Recruiting |
NCT01876017 -
Safety and Efficacy of BMMNC in Patients With Chronic Renal Failure
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT03019159 -
Assessment of a Follow-up With Tele-consulting for Patients With Renal Failure Under Peritoneal Dialysis
|
N/A | |
| Completed |
NCT02047006 -
Dose-finding of Rivaroxaban in Hemodialysis
|
Phase 4 | |
| Completed |
NCT01617824 -
Rapid Effects Linagliptin on Monocyte Polarization and Endothelial Progenitor Cells in Type 2 Diabetes
|
Phase 4 | |
| Completed |
NCT00597753 -
Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis
|
Phase 3 | |
| Completed |
NCT00828776 -
Pharmacodynamics and Non-Clinical Inferiority of Heparin Sodium (Cristália) Compared With the Product Liquemine (Roche) in Chronic Renal Failure
|
Phase 2/Phase 3 | |
| Completed |
NCT00379899 -
ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis
|
Phase 4 | |
| Terminated |
NCT00372489 -
Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD
|
Phase 2 | |
| Completed |
NCT00228436 -
Safety, PD & PK of Multiple Doses of Peginesatide for Anemia in Chronic Kidney Disease Patients
|
Phase 2 | |
| Completed |
NCT03772171 -
Estimate for Dietary Intakes and Hemodialysis Patients
|
||
| Recruiting |
NCT02586402 -
Safety & Efficacy of Pegolsihematide for Treatment of Anemia in Participants on Dialysis
|
Phase 2 | |
| Completed |
NCT01879618 -
Use Of Fragmin In Hemodialysis
|
Phase 3 | |
| Not yet recruiting |
NCT01346215 -
Study of Clinical Non-inferiority of Actparin® (Laboratorio Bergamo) Compared to Heparin Sodium (APP Pharmaceuticals), in Patients With Chronic Renal Failure
|
Phase 3 | |
| Completed |
NCT01220843 -
FGF23 Reduction : Efficacy of a New Phosphate Binder in CHronic Kidney Disease
|
Phase 3 | |
| Completed |
NCT01111630 -
Study of Erythropoietin (EPO) Administration Schedule
|
Phase 4 | |
| Completed |
NCT00742716 -
Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease
|
Phase 2 | |
| Completed |
NCT00597584 -
Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis
|
Phase 3 | |
| Completed |
NCT00598273 -
Safety & Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis
|
Phase 3 |